Experimental hepatitis c vaccine enters first human safety trial

NCT ID NCT07237282

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: University of Alberta Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial will test an experimental vaccine against hepatitis C (HCV) in 27 healthy adults. The main goal is to see if the vaccine is safe and to measure the immune response it triggers. Participants will receive three shots over 24 weeks and be closely monitored for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AVIHepC1 (experimental HCV vaccine with adjuvant)
What this could lead to: If successful, this could pave the way for a vaccine to prevent hepatitis C infection.
What could go wrong: This is a very early phase 1 trial with only 27 healthy adults, focused on safety. It is too soon to know if the vaccine will actually prevent infection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATITIS C

Contacts and locations

Locations

Ottawa Hospital - General Campus

Ottawa, Ontario, K1H 8L6, Canada
Toronto General Hospital - Toronto Centre for Liver Disease

Toronto, Ontario, M5G 2C4, Canada
University of Alberta Hospital

Edmonton, Alberta, T6G 2B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.